Гриснилимаб сетаритокс

Rec. INN (наименование, зарегистрированное ВОЗ)

2361013-29-6

immunoglobulin G2A-lambda, anti-[CD7 (CD7 antigen (p41), GP40, LEU-9, TP41, Tp40)], Mus musculus monoclonal antibody conjugated to ricin toxin A (RTA);
gamma2a heavy chain Mus musculus (1-453) [VH (Mus musculus  IGHV9-3-1*01 (98%) -(IGHD) -IGHJ2*01 (93.3%)) CDR-IMGT [8.8.16] (26-33.51-58.97-112) (1-123) -Mus musculus IGHG2A*01 (100%) (CH1 (124-220), hinge 1-16 (221-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (138-214’)-disulfide with lambda light chain Mus musculus (1’-215’) [V-LAMBDA (Mus musculus IGLV1*01 (98%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.9] (26-34.52-54.91-99) (1’-109’) -Mus musculus IGLC1*01 (100%) (110’-215’)];
dimer (230-230":233-233":235-235")-trisdisulfide, glycoform alfa, produced in SP2/0-derived mouse myeloma cells, substituted at N⁶ of an average of 1.6 lysyl residues with 4-[(1RS)-1-{[l-methionyl-ricin toxin A-chain (Met-RTA, non-glycosylated, produced in Escherichia coli)-S²⁶⁰-yl]sulfanyl}ethyl]benzoyl groups

Поделиться этой страницей